A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
← catalyst calendarNCT07325136 · readout in 978 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
240estimated
Sites
13
Countries
China, Italy, Japan +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-02-03 | actual | When the study began enrolling |
| Primary completion | 2029-04-23 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-04-24 | estimated | The whole study's end, after follow-up |
| First posted | 2026-01-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Relapsed/Refractory Small Cell Lung Cancer
Interventions
- Drug: BMS-986525
- Drug: Pumitamig — also filed as BNT-327, BMS-986545
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with adverse events (AEs)
measured Up to approximately 2 years
Number of participants with serious adverse events (SAEs)
measured Up to approximately 2 years
Number of participants with AEs meeting dose-limiting toxicity (DLT) criteria
measured Up to 21 days
Number of participants with AEs leading to discontinuation
measured Up to approximately 2 years
Number of participants with AEs leading to death
measured Up to approximately 2 years
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed